Patent: 8,501,417
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,501,417
Title: | Immunological compositions as cancer biomarkers and/or therapeutics |
Abstract: | The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example. |
Inventor(s): | Pohlmann; Paula R. (Nashville, TN), Mernaugh; Ray (Nashville, TN), Arteaga; Carlos (Nashville, TN) |
Assignee: | Vanderbilt University (Nashville, TN) |
Application Number: | 12/666,566 |
Patent Claims: | see list of patent claims |
Details for Patent 8,501,417
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2027-06-26 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | See Plans and Pricing | 2027-06-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2027-06-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2027-06-26 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | See Plans and Pricing | 2027-06-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |